top of page
VL (980 x 350 px) (3).png

Workshop
Pre-reading

Monday 29 April 2024

To ensure our workshops are as productive as possible, we've gathered pre-reading materials that offer practical insights into the issues at hand. Please take time to read the pre-reading for your allocated workshop beforehand, that way you'll be equipped with the knowledge and perspective needed to contribute meaningfully to our discussions. 

Please note: Members of the media are not permitted to attend the Summit workshops.

Background for Workshop Tiles.png
Sarah Hogan.png

Chair - Sarah Hogan

Deputy Chief Executive (Wellington) and Principal Economist NZIER

Workshop 1

Enhancing HTA Processes in New Zealand

PANEL:

  • Chris Carswell: Editor in Chief of Pharmaco Economics and the Editor in Chief of The Patient for Springer Nature Journals

  • Dr Jane Thomas - PTAC Chair

  • Dr Greg Cook - Director of Access Policy and Advocacy for Bristol Myers Squibb Australia and New Zealand

  • Ben Campbell-MacDonald - Senior Health Economist Pharmac

  • Christine Perrins - Advocacy Adviser, Cystic Fibrosis NZ

This workshop will focus on discussion of  potential enhancements to the existing health technology assessment (HTA ) processes  in New Zealand  using a holistic approach to costs and benefits. The session will include discussion on learnings that can be adopted from overseas to suit the New Zealand system.

WORKSHOP QUESTIONS:

  1. What does a good HTA process look like? 

  2. What adjustments, if any, would be required in New Zealand to achieve this outcome? 

  3. What actions are needed to start the enhancement processes, and who would be responsible for them? 

Background for Workshop Tiles.png
Lee Mathias.png

Chair - Dr Lee Mathias, ONZM Independent Director, former Chair at HPA, Medicines New Zealand and Counties Manukau DHB

Workshop 2

Building a fit-for-purpose Medicines Strategy for New Zealand

PANEL:

  • Prof. John Zalcberg - All.Can Australia Board Director, Department of Epidemiology and Preventative Medicine, Monash University & Dept of Medical Oncology, Alfred Health, Melbourne, Australia

  • Dr Peter Jansen - Chief Executive of Health Quality & Safety Commission

  • Maree Roberts - Deputy Director-General, Strategy Policy and Legislation at the Ministry of Health

  • Libby Burgess - Chair Breast Cancer Aotearoa Coalition (BCAC)

  • Andrew Gaudin - Chief Executive of Pharmacy Guild of New Zealand
  • Vanessa Gascoigne - Director for Merck Sharp & Dohme (MSD) in Aotearoa New Zealand

This workshop will focus on establishing core themes and elements for a modernised medicines strategy that will both allow greater certainty for all health sector stakeholders and help future-proof the health system.

WORKSHOP QUESTIONS:

  1. What should a good Medicines Strategy look like and have as core elements? 

  2. What adjustments, if any, would be required in New Zealand’s existing 2007 Strategy to achieve this outcome? 

  3. What actions are needed to start the enhancement processes, and who would be responsible for them? 

Background for Workshop Tiles.png
Sue Chetwin.png

Chair - Sue Chetwin, LLB CNZM,

Chair of the Pharmac Review Consumer Advocate

Workshop 3

Better stakeholder engagement in decision-making processes

PANEL:

  • Richard Vines - Chair Rare Cancers Australia

  • Dr Robyn Manuel - Chair of Pharmac Consumer Advisory Committee

  • Dr Rodger Tiedemann - Consultant Haematologist | Cancer and Blood Service

  • Dr David Hughes - Chief Medical Officer Pharmac

  • Fiona Tolich - Spinal Muscular Atrophy (SMA) and Patient Advocate

  • Tony Davison - Business Unit Manager, Boehringer Ingleheim New Zealand

This workshop will investigate the key enablers necessary to allow all stakeholders, but particularly the patient/consumer voice, the ability to have inputs into decision-making processes  undertaken on medicines procurement.

WORKSHOP QUESTIONS:

  1. What does a good consumer engagement in decision-making processes around medicines look like? 

  2. What adjustments, if any, would be required in New Zealand to achieve this outcome? 

  3. What actions are needed to start the enhancement processes, and who would be responsible for them? 

Background for Workshop Tiles.png
Christian Schwabe.png

Chair - Dr Christian Schwabe, MD, MPharm Med

CEO, Senior Research Physician NZ Clinical Research

Workshop 4

Health Innovation Optimisation in New Zealand (precision health, clinical research, horizon scanning)

PANEL:

  • Prof David Thomas - CEO Omico, Director Australian Genomic Cancer Medicine Centre, Garvan Institute of Medical Research

  • Professor Ian Town, MBChB, DM, FRACP - Chief Science Advisor, Manatū Hauora |The Ministry of Health

  • Katrina Lapham - Director Strategic Market Access and Policy, Biointelect

  • David Downs - CEO of NZ Story and Patient Advocate

  • Marina Dzhelali - New Zealand Association of Clinical Research (NZACRes) Executive Committee

  • Alex Muelhaupt - General Manager, Roche Pharmaceuticals New Zealand and Director Roche Diagnostics

  • Dr Ben Lawrence - Senior Clinical Research Fellow and Medical Oncologist

This workshop will determine what the critical success factors are to optimise implementation of three key health research and innovation platforms in New Zealand:  a "1 stop shop " for human pharmaceutical clinical trials;   a unified health technology horizon scanning  system, and;  a precision medicines platform.

WORKSHOP QUESTIONS:

  1. What are the critical success factors for best practice Health Innovation Optimisation in clinical trial, precision medicines and horizon scanning? 

  2. What adjustments, if any, would be required in New Zealand to achieve this outcome in each area (clinical trials, precision health/medicines and Horizon scanning)?  

  3. What actions are needed to start the enhancement processes in each of the 3 areas (clinical trials, precision health/medicines and Horizon scanning), and who would be responsible for them? 

"Attendee Disclaimer

By attending this Summit, you are acknowledging the following matters and rules applying to the conduct of the Summit, and agreeing to acting in accordance with them:

The attendees of the Event acknowledge that they understand the views and opinions expressed during the Event are those of each individual speaker/panellist and do not necessarily reflect the views or position of Medicines New Zealand or Patient Voice Aotearoa. The Summit has been organised to provide an opportunity for high-level discussion among a diverse range of local and international stakeholders in the health and medicine sector. Accordingly, the organisers have provided a platform for the speakers/panellists to express their own personal views and opinions. 

 

During the Event the moderator will indicate when a session/panel event is subject to Chatham House Rule. Under the Chatham House Rule, participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed. The aim of Chatham House Rule is to bring people together, break down barriers, generate ideas and agree solutions. The attendees of the Summit agree and acknowledge that it is therefore of vital importance that what is said whilst Chatham House Rules apply, is not repeated or disclosed outside of the session."

bottom of page